BG63126B1 - Лечебни препарати на основата на нуклеинови киселини - Google Patents

Лечебни препарати на основата на нуклеинови киселини Download PDF

Info

Publication number: BG63126B1
Authority: BG; Bulgaria
Prior art keywords: seq; dna; gene; influenza; vijns
Prior art date: 1993-03-18

Application number

BG100006A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG100006A (bg

Inventor

John Donnelly

Varavani Dwarki

Margaret Liu

Donna Montgomery

Suezanne Parker

John SHIVER

Jeffrey Ulmer

Original Assignee

Merck & Co. Inc.

Vical Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-18

Filing date

1995-09-18

Publication date

2001-04-30

1995-09-18 Application filed by Merck & Co. Inc., Vical Incorporated filed Critical Merck & Co. Inc.

1996-12-31 Publication of BG100006A publication Critical patent/BG100006A/bg

2001-04-30 Publication of BG63126B1 publication Critical patent/BG63126B1/bg

Links

150000007523 nucleic acids Chemical class 0.000 title claims description 76
102000039446 nucleic acids Human genes 0.000 title claims description 74
108020004707 nucleic acids Proteins 0.000 title claims description 74
238000002360 preparation method Methods 0.000 title description 12
108090000623 proteins and genes Proteins 0.000 claims abstract description 212
241000700605 Viruses Species 0.000 claims abstract description 84
241000712461 unidentified influenza virus Species 0.000 claims abstract description 80
208000015181 infectious disease Diseases 0.000 claims abstract description 75
102000004169 proteins and genes Human genes 0.000 claims abstract description 69
241001465754 Metazoa Species 0.000 claims abstract description 60
230000004224 protection Effects 0.000 claims abstract description 52
239000003814 drug Substances 0.000 claims abstract description 12
206010022000 influenza Diseases 0.000 claims description 116
108010061100 Nucleoproteins Proteins 0.000 claims description 96
229960005486 vaccine Drugs 0.000 claims description 96
102000011931 Nucleoproteins Human genes 0.000 claims description 94
239000013598 vector Substances 0.000 claims description 89
101710154606 Hemagglutinin Proteins 0.000 claims description 84
101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 84
101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 84
101710176177 Protein A56 Proteins 0.000 claims description 84
239000000185 hemagglutinin Substances 0.000 claims description 77
210000004027 cell Anatomy 0.000 claims description 71
230000003612 virological effect Effects 0.000 claims description 58
230000003053 immunization Effects 0.000 claims description 49
238000002649 immunization Methods 0.000 claims description 48
230000028993 immune response Effects 0.000 claims description 45
230000004044 response Effects 0.000 claims description 45
239000013612 plasmid Substances 0.000 claims description 43
238000000034 method Methods 0.000 claims description 42
230000014509 gene expression Effects 0.000 claims description 41
241000845082 Panama Species 0.000 claims description 36
239000013604 expression vector Substances 0.000 claims description 25
230000001681 protective effect Effects 0.000 claims description 23
230000003472 neutralizing effect Effects 0.000 claims description 19
201000010099 disease Diseases 0.000 claims description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
230000000890 antigenic effect Effects 0.000 claims description 16
238000010276 construction Methods 0.000 claims description 16
239000000203 mixture Substances 0.000 claims description 16
238000002255 vaccination Methods 0.000 claims description 16
238000001727 in vivo Methods 0.000 claims description 13
239000003795 chemical substances by application Substances 0.000 claims description 11
108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims description 10
230000009385 viral infection Effects 0.000 claims description 9
230000001939 inductive effect Effects 0.000 claims description 8
239000011159 matrix material Substances 0.000 claims description 8
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 7
229940079593 drug Drugs 0.000 claims description 6
238000010348 incorporation Methods 0.000 claims description 6
238000013518 transcription Methods 0.000 claims description 6
230000035897 transcription Effects 0.000 claims description 6
238000013519 translation Methods 0.000 claims description 6
108700005077 Viral Genes Proteins 0.000 claims description 5
231100000433 cytotoxic Toxicity 0.000 claims description 5
230000001472 cytotoxic effect Effects 0.000 claims description 5
239000002502 liposome Substances 0.000 claims description 5
238000001890 transfection Methods 0.000 claims description 5
108060003393 Granulin Proteins 0.000 claims description 4
101710172711 Structural protein Proteins 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 4
230000001105 regulatory effect Effects 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
230000002708 enhancing effect Effects 0.000 claims description 3
230000000977 initiatory effect Effects 0.000 claims description 3
238000003780 insertion Methods 0.000 claims description 3
230000037431 insertion Effects 0.000 claims description 3
210000004698 lymphocyte Anatomy 0.000 claims description 3
241001500351 Influenzavirus A Species 0.000 claims description 2
-1 polymerase Proteins 0.000 claims description 2
241000714230 Avian leukemia virus Species 0.000 claims 1
241000700662 Fowlpox virus Species 0.000 claims 1
210000004102 animal cell Anatomy 0.000 claims 1
238000002955 isolation Methods 0.000 claims 1
238000002347 injection Methods 0.000 abstract description 77
239000007924 injection Substances 0.000 abstract description 77
230000000069 prophylactic effect Effects 0.000 abstract description 4
108020004414 DNA Proteins 0.000 description 192
241000699670 Mus sp. Species 0.000 description 188
108020004635 Complementary DNA Proteins 0.000 description 74
238000010804 cDNA synthesis Methods 0.000 description 74
239000002299 complementary DNA Substances 0.000 description 71
230000000692 anti-sense effect Effects 0.000 description 65
235000018102 proteins Nutrition 0.000 description 55
239000012634 fragment Substances 0.000 description 43
239000011148 porous material Substances 0.000 description 38
241000282339 Mustela Species 0.000 description 37
239000000047 product Substances 0.000 description 30
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 29
108091007433 antigens Proteins 0.000 description 27
102000036639 antigens Human genes 0.000 description 26
239000000427 antigen Substances 0.000 description 25
230000015572 biosynthetic process Effects 0.000 description 25
208000037797 influenza A Diseases 0.000 description 24
238000010968 computed tomography angiography Methods 0.000 description 23
238000003752 polymerase chain reaction Methods 0.000 description 23
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 20
230000004083 survival effect Effects 0.000 description 20
230000036039 immunity Effects 0.000 description 19
230000029142 excretion Effects 0.000 description 18
108090000765 processed proteins & peptides Proteins 0.000 description 18
210000002966 serum Anatomy 0.000 description 18
210000004989 spleen cell Anatomy 0.000 description 17
108010006025 bovine growth hormone Proteins 0.000 description 16
230000009089 cytolysis Effects 0.000 description 16
210000003205 muscle Anatomy 0.000 description 16
241000282693 Cercopithecidae Species 0.000 description 15
241000282412 Homo Species 0.000 description 15
238000012360 testing method Methods 0.000 description 15
230000004580 weight loss Effects 0.000 description 15
101150118742 NP gene Proteins 0.000 description 14
238000004458 analytical method Methods 0.000 description 14
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 13
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 13
230000007423 decrease Effects 0.000 description 13
230000001965 increasing effect Effects 0.000 description 13
210000004072 lung Anatomy 0.000 description 13
210000001519 tissue Anatomy 0.000 description 13
241000288906 Primates Species 0.000 description 12
102100037516 Protein polybromo-1 Human genes 0.000 description 12
101710085035 RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
229960003971 influenza vaccine Drugs 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
241000699666 Mus <mouse, genus> Species 0.000 description 11
101710102873 Polymerase basic protein 2 Proteins 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
101150039660 HA gene Proteins 0.000 description 10
108010067390 Viral Proteins Proteins 0.000 description 10
210000003414 extremity Anatomy 0.000 description 10
238000000338 in vitro Methods 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
101710158312 DNA-binding protein HU-beta Proteins 0.000 description 9
102100029241 Influenza virus NS1A-binding protein Human genes 0.000 description 9
101710128560 Initiator protein NS1 Proteins 0.000 description 9
101710144127 Non-structural protein 1 Proteins 0.000 description 9
230000034994 death Effects 0.000 description 9
231100000517 death Toxicity 0.000 description 9
230000000694 effects Effects 0.000 description 9
230000028996 humoral immune response Effects 0.000 description 9
210000000663 muscle cell Anatomy 0.000 description 9
108091033319 polynucleotide Proteins 0.000 description 9
102000040430 polynucleotide Human genes 0.000 description 9
239000002157 polynucleotide Substances 0.000 description 9
230000002685 pulmonary effect Effects 0.000 description 9
230000010076 replication Effects 0.000 description 9
108091008146 restriction endonucleases Proteins 0.000 description 9
230000028327 secretion Effects 0.000 description 9
238000002965 ELISA Methods 0.000 description 8
230000005875 antibody response Effects 0.000 description 8
238000013459 approach Methods 0.000 description 8
235000013601 eggs Nutrition 0.000 description 8
230000006870 function Effects 0.000 description 8
230000035931 haemagglutination Effects 0.000 description 8
230000035772 mutation Effects 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
238000000926 separation method Methods 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
108020000999 Viral RNA Proteins 0.000 description 7
238000010219 correlation analysis Methods 0.000 description 7
230000000875 corresponding effect Effects 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
210000003098 myoblast Anatomy 0.000 description 7
241000282552 Chlorocebus aethiops Species 0.000 description 6
102000000588 Interleukin-2 Human genes 0.000 description 6
108010002350 Interleukin-2 Proteins 0.000 description 6
238000000246 agarose gel electrophoresis Methods 0.000 description 6
230000008901 benefit Effects 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
230000005847 immunogenicity Effects 0.000 description 6
230000001976 improved effect Effects 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
239000013642 negative control Substances 0.000 description 6
238000012163 sequencing technique Methods 0.000 description 6
239000007787 solid Substances 0.000 description 6
210000002845 virion Anatomy 0.000 description 6
108091026890 Coding region Proteins 0.000 description 5
230000024932 T cell mediated immunity Effects 0.000 description 5
208000036142 Viral infection Diseases 0.000 description 5
125000003275 alpha amino acid group Chemical group 0.000 description 5
239000012636 effector Substances 0.000 description 5
239000012530 fluid Substances 0.000 description 5
230000007062 hydrolysis Effects 0.000 description 5
238000006460 hydrolysis reaction Methods 0.000 description 5
230000002458 infectious effect Effects 0.000 description 5
230000002401 inhibitory effect Effects 0.000 description 5
238000007918 intramuscular administration Methods 0.000 description 5
230000002688 persistence Effects 0.000 description 5
230000002265 prevention Effects 0.000 description 5
229920002477 rna polymer Polymers 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
206010002091 Anaesthesia Diseases 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
229940021995 DNA vaccine Drugs 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
241000287828 Gallus gallus Species 0.000 description 4
102000005348 Neuraminidase Human genes 0.000 description 4
108010006232 Neuraminidase Proteins 0.000 description 4
108091092724 Noncoding DNA Proteins 0.000 description 4
206010057190 Respiratory tract infections Diseases 0.000 description 4
210000001744 T-lymphocyte Anatomy 0.000 description 4
206010052428 Wound Diseases 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
239000000853 adhesive Substances 0.000 description 4
230000001070 adhesive effect Effects 0.000 description 4
239000011543 agarose gel Substances 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
230000037005 anaesthesia Effects 0.000 description 4
238000010171 animal model Methods 0.000 description 4
235000013330 chicken meat Nutrition 0.000 description 4
230000000295 complement effect Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
230000006698 induction Effects 0.000 description 4
229930027917 kanamycin Natural products 0.000 description 4
229960000318 kanamycin Drugs 0.000 description 4
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
229930182823 kanamycin A Natural products 0.000 description 4
230000021633 leukocyte mediated immunity Effects 0.000 description 4
239000013641 positive control Substances 0.000 description 4
238000011084 recovery Methods 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
241000701022 Cytomegalovirus Species 0.000 description 3
108010041986 DNA Vaccines Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229930193140 Neomycin Natural products 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
206010039491 Sarcoma Diseases 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
238000000540 analysis of variance Methods 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
230000009260 cross reactivity Effects 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
235000013882 gravy Nutrition 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
238000003119 immunoblot Methods 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
239000002054 inoculum Substances 0.000 description 3
238000010255 intramuscular injection Methods 0.000 description 3
231100000518 lethal Toxicity 0.000 description 3
230000001665 lethal effect Effects 0.000 description 3
238000001823 molecular biology technique Methods 0.000 description 3
210000000107 myocyte Anatomy 0.000 description 3
229960004927 neomycin Drugs 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
210000001331 nose Anatomy 0.000 description 3
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
238000012545 processing Methods 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
230000008707 rearrangement Effects 0.000 description 3
230000001850 reproductive effect Effects 0.000 description 3
238000012770 revaccination Methods 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
230000001629 suppression Effects 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
238000004448 titration Methods 0.000 description 3
238000011282 treatment Methods 0.000 description 3
210000000689 upper leg Anatomy 0.000 description 3
229960004854 viral vaccine Drugs 0.000 description 3
229920000936 Agarose Polymers 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 2
108010062580 Concanavalin A Proteins 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
238000011238 DNA vaccination Methods 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
241000712431 Influenza A virus Species 0.000 description 2
241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 2
102100024319 Intestinal-type alkaline phosphatase Human genes 0.000 description 2
101710184243 Intestinal-type alkaline phosphatase Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
101150076514 NS gene Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
101150103639 PB1 gene Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
108010003533 Viral Envelope Proteins Proteins 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
201000011040 acute kidney failure Diseases 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000003556 assay Methods 0.000 description 2
235000015278 beef Nutrition 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
244000309466 calf Species 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
239000010931 gold Substances 0.000 description 2
229910052737 gold Inorganic materials 0.000 description 2
230000005745 host immune response Effects 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
239000007927 intramuscular injection Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000005923 long-lasting effect Effects 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
230000000474 nursing effect Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000037361 pathway Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
201000009410 rhabdomyosarcoma Diseases 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
239000013026 undiluted sample Substances 0.000 description 2
230000001018 virulence Effects 0.000 description 2
FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
101150002210 34 gene Proteins 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
241001209177 Akis Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
201000001178 Bacterial Pneumonia Diseases 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
101150044789 Cap gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
241000867607 Chlorocebus sabaeus Species 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
FCKYPQBAHLOOJQ-UHFFFAOYSA-N Cyclohexane-1,2-diaminetetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)C1CCCCC1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-UHFFFAOYSA-N 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
241000255925 Diptera Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
108700007698 Genetic Terminator Regions Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
241000252870 H3N2 subtype Species 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102000025850 HLA-A2 Antigen Human genes 0.000 description 1
108010074032 HLA-A2 Antigen Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
208000032376 Lung infection Diseases 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
241000219823 Medicago Species 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
241000282341 Mustela putorius furo Species 0.000 description 1
101150033828 NS1 gene Proteins 0.000 description 1
102000035028 Nucleic proteins Human genes 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101150084044 P gene Proteins 0.000 description 1
101150030427 PB2 gene Proteins 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108010064851 Plant Proteins Proteins 0.000 description 1
206010035737 Pneumonia viral Diseases 0.000 description 1
241000206607 Porphyra umbilicalis Species 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
208000034712 Rickettsia Infections Diseases 0.000 description 1
WHSQPVUDHQAQLA-UHFFFAOYSA-N SSSSSSSSSS Chemical compound SSSSSSSSSS WHSQPVUDHQAQLA-UHFFFAOYSA-N 0.000 description 1
241000831652 Salinivibrio sharmensis Species 0.000 description 1
101710165315 Sialidase A Proteins 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
206010046306 Upper respiratory tract infection Diseases 0.000 description 1
206010058874 Viraemia Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
230000027645 antigenic variation Effects 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
230000008827 biological function Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
210000004413 cardiac myocyte Anatomy 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
235000019365 chlortetracycline Nutrition 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
229940001442 combination vaccine Drugs 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229940028617 conventional vaccine Drugs 0.000 description 1
230000000139 costimulatory effect Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
230000007402 cytotoxic response Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000005860 defense response to virus Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
108020001096 dihydrofolate reductase Proteins 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
210000002472 endoplasmic reticulum Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
150000002085 enols Chemical class 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000011832 ferret model Methods 0.000 description 1
239000003337 fertilizer Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
238000010359 gene isolation Methods 0.000 description 1
230000035784 germination Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000007233 immunological mechanism Effects 0.000 description 1
230000006054 immunological memory Effects 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
208000037798 influenza B Diseases 0.000 description 1
229940033326 influenza DNA vaccine Drugs 0.000 description 1
108700010900 influenza virus proteins Proteins 0.000 description 1
230000030214 innervation Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000016507 interphase Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
229940090046 jet injector Drugs 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
101150109249 lacI gene Proteins 0.000 description 1
239000002523 lectin Substances 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
238000007169 ligase reaction Methods 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
201000006512 mast cell neoplasm Diseases 0.000 description 1
208000006971 mastocytoma Diseases 0.000 description 1
230000035800 maturation Effects 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
230000015654 memory Effects 0.000 description 1
239000003595 mist Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000005088 multinucleated cell Anatomy 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000035778 pathophysiological process Effects 0.000 description 1
101150027243 pb gene Proteins 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940023041 peptide vaccine Drugs 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
235000021118 plant-derived protein Nutrition 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
230000009993 protective function Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
229940023143 protein vaccine Drugs 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000009666 routine test Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
210000002363 skeletal muscle cell Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000003393 splenic effect Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
229940031626 subunit vaccine Drugs 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
101150065190 term gene Proteins 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229940031418 trivalent vaccine Drugs 0.000 description 1
108700026220 vif Genes Proteins 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
208000009421 viral pneumonia Diseases 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Peptides Or Proteins (AREA)

BG100006A 1993-03-18 1995-09-18 Лечебни препарати на основата на нуклеинови киселини BG63126B1 (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US3238393A	1993-03-18	1993-03-18
US8998593A	1993-07-08	1993-07-08
PCT/US1994/002751 WO1994021797A1 (en)	1993-03-18	1994-03-14	Nucleic acid pharmaceuticals

Publications (2)

Publication Number	Publication Date
BG100006A BG100006A (bg)	1996-12-31
BG63126B1 true BG63126B1 (bg)	2001-04-30

Family

ID=26708344

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG100006A BG63126B1 (bg)	1993-03-18	1995-09-18	Лечебни препарати на основата на нуклеинови киселини

Country Status (22)

Country	Link
EP (1)	EP0620277A1 (zh)
JP (2)	JP2812352B2 (zh)
CN (1)	CN1119458A (zh)
AU (1)	AU676258B2 (zh)
BG (1)	BG63126B1 (zh)
BR (1)	BR9406007A (zh)
CA (1)	CA2119175A1 (zh)
CZ (1)	CZ290315B6 (zh)
DZ (1)	DZ1759A1 (zh)
FI (1)	FI954329A0 (zh)
HR (1)	HRP940175A2 (zh)
HU (1)	HUT73397A (zh)
IL (1)	IL108915A0 (zh)
NO (1)	NO953649L (zh)
NZ (1)	NZ263680A (zh)
PL (1)	PL178626B1 (zh)
RO (1)	RO117710B1 (zh)
SI (1)	SI9420014A (zh)
SK (1)	SK114295A3 (zh)
UA (1)	UA42715C2 (zh)
WO (1)	WO1994021797A1 (zh)
YU (1)	YU12894A (zh)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849719A (en)	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US6911216B1 (en)	1994-10-12	2005-06-28	Genzyme Corporation	Targeted delivery via biodegradable polymers
US5736524A (en) *	1994-11-14	1998-04-07	Merck & Co.,. Inc.	Polynucleotide tuberculosis vaccine
DE19512142A1 (de) *	1995-03-31	1996-10-02	Immuno Ag	Infektiöser cDNA-Klon des Tick-Borne Enzephalitis (TBE)-Virus, davon abgeleiteter rekombinanter Impfstoff und Herstellung desselben sowie ein pharmazeutisches Produkt, das eine replizierbare Nukleinsäure enthält
US6019980A (en)	1995-06-07	2000-02-01	Connaught Laboratories Limited	Nucleic acid respiratory syncytial virus vaccines
US6017897A (en) *	1995-06-07	2000-01-25	Pasteur Merieux Connaught Canada	Nucleic acid respiratory syncytial virus vaccines
US6083925A (en) *	1995-06-07	2000-07-04	Connaught Laboratories Limited	Nucleic acid respiratory syncytial virus vaccines
US6537776B1 (en)	1999-06-14	2003-03-25	Diversa Corporation	Synthetic ligation reassembly in directed evolution
FR2751225B1 (fr) *	1996-07-19	1998-11-27	Rhone Merieux	Formule de vaccin polynucleotidique aviaire
US6204250B1 (en)	1996-11-22	2001-03-20	The Mount Sinai Medical Center Of The City Of New York	Immunization of infants
WO1998035562A1 (en) *	1997-02-14	1998-08-20	Merck & Co., Inc.	Polynucleotide vaccine formulations
US6517843B1 (en)	1999-08-31	2003-02-11	Merial	Reduction of porcine circovirus-2 viral load with inactivated PCV-2
UA78180C2 (uk)	1997-10-03	2007-03-15	Меріаль	Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
FR2772047B1 (fr)	1997-12-05	2004-04-09	Ct Nat D Etudes Veterinaires E	Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6693087B1 (en)	1998-08-20	2004-02-17	Aventis Pasteur Limited	Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en)	1998-08-20	2004-02-03	Aventis Pasteur Limited	Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
CA2340330A1 (en)	1998-08-20	2000-03-02	Aventis Pasteur Limited	Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
US6881723B1 (en)	1998-11-05	2005-04-19	Powderject Vaccines, Inc.	Nucleic acid constructs
US7618797B2 (en)	1998-12-22	2009-11-17	Pfizer Inc	Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7691389B2 (en)	1998-12-22	2010-04-06	Pfizer Inc	Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
AU3593200A (en)	1999-02-09	2000-08-29	Powderject Vaccines, Inc.	(mycobacterium tuberculosis), immunization
US6943152B1 (en)	1999-06-10	2005-09-13	Merial	DNA vaccine-PCV
JP2001151698A (ja) *	1999-09-10	2001-06-05	Nichiko Pharmaceutical Co Ltd	インフルエンザワクチン
ES2306670T3 (es)	1999-10-22	2008-11-16	Sanofi Pasteur Limited	Procedimiento de induccion y/o intensificacion de la respuesta inmunitaria frente a antigenos tumorales.
US7196066B1 (en)	1999-11-03	2007-03-27	Powderject Vaccines, Inc.	DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US7078388B2 (en)	2000-01-21	2006-07-18	Merial	DNA vaccines for farm animals, in particular bovines and porcines
US6852705B2 (en)	2000-01-21	2005-02-08	Merial	DNA vaccines for farm animals, in particular bovines and porcines
EP1792995A3 (en)	2000-05-08	2007-06-13	Sanofi Pasteur Limited	Chlamydia secretory locus orf and uses thereof
AU5810201A (en)	2000-05-10	2001-11-20	Aventis Pasteur	Immunogenic polypeptides encoded by mage minigenes and uses thereof
CA2566355C (en)	2004-05-18	2014-04-15	Vical Incorporated	Influenza virus vaccine composition and methods of use
US8202967B2 (en)	2006-10-27	2012-06-19	Boehringer Ingelheim Vetmedica, Inc.	H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
EP2152871A4 (en)	2007-05-31	2011-01-05	Becton Dickinson Co	SEQUENCES AND METHOD FOR DETECTING INFLUENZA VIRUS A AND INFLUENZA VIRUS B
US8354230B2 (en) *	2007-12-21	2013-01-15	Quest Diagnostics Investments Inc.	Multiplex detection assay for influenza and RSV viruses
EP2318044B1 (en)	2008-08-01	2015-12-02	Gamma Vaccines Pty Limited	Influenza vaccines
CA2760553A1 (en)	2009-04-30	2010-11-04	Jr. James E. Crowe	Monoclonal antibodies to influenza h1n1 virus and uses thereof
SG168423A1 (en) *	2009-07-13	2011-02-28	Agency Science Tech & Res	Influenza detection method and kit therefor
AR078253A1 (es)	2009-09-02	2011-10-26	Boehringer Ingelheim Vetmed	Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
AR083533A1 (es)	2010-10-22	2013-03-06	Boehringer Ingelheim Vetmed	Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
AR088028A1 (es)	2011-08-15	2014-05-07	Boehringer Ingelheim Vetmed	Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en)	2011-09-03	2013-03-07	Boehringer Ingelheim Vetmedica Gmbh	Streptococcus suis pilus antigens
US10383835B2 (en)	2012-03-14	2019-08-20	The Regents Of The University Of California	Treatment of inflammatory disorders in non-human mammals
WO2014127825A1 (en)	2013-02-21	2014-08-28	Boehringer Ingelheim Vetmedica Gmbh	H5 proteins of h5n1 influenza virus for use as a medicament
EP2976357B1 (en) *	2013-03-18	2018-10-17	Osivax SAS	Influenza nucleoprotein vaccines
EP4091629A1 (en)	2013-09-25	2022-11-23	Zoetis Services LLC	Pcv2b divergent vaccine composition and methods of use
CA2943816A1 (en)	2014-04-03	2015-10-08	Boehringer Ingelheim Vetmedica, Inc.	Porcine epidemic diarrhea virus vaccine
DK3344289T3 (da)	2015-08-31	2020-04-14	Boehringer Ingelheim Vetmedica Gmbh	Pestivirusvacciner mod medfødt tremor
CA2996613A1 (en)	2015-09-16	2017-03-23	Boehringer Ingelheim Vetmedica, Inc.	Salmonella choleraesuis-salmonella typhimurium vaccines
JP6952112B2 (ja)	2016-09-20	2021-10-20	ベーリンガーインゲルハイムフェトメディカゲーエムベーハーＢｏｅｈｒｉｎｇｅｒＩｎｇｅｌｈｅｉｍＶｅｔｍｅｄｉｃａＧｍｂＨ	新規なｅｈｖ挿入部位ｏｒｆ７０
CN110072546B (zh)	2016-09-20	2023-10-31	勃林格殷格翰动物保健有限公司	新的猪流感疫苗
CA3036386A1 (en)	2016-09-20	2018-03-29	Boehringer Ingelheim Vetmedica Gmbh	Canine adenovirus vectors
TWI780070B (zh)	2016-09-20	2022-10-11	德商百靈佳殷格翰維美迪加股份有限公司	新穎之啟動子
MX2019005136A (es)	2016-11-03	2019-06-20	Boehringer Ingelheim Vetmedica Gmbh	Vacuna contra el parvovirus porcino y el virus del sindrome respiratorio reproductivo porcino y metodos de produccion de esta.
BR112019009133A2 (pt)	2016-11-03	2019-07-16	Boehringer Ingelheim Vetmedica Gmbh	vacina contra o parvovírus suíno
EA201991762A1 (ru)	2017-01-30	2020-01-23	Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк.	Вакцины против коронавируса свиней
CN110869047A (zh)	2017-07-12	2020-03-06	勃林格殷格翰动物保健美国有限公司	塞内卡病毒a免疫原性组合物及其方法
MX2020003071A (es)	2017-09-23	2020-07-28	Boehringer Ingelheim Vetmedica Gmbh	Sistema de expresion de paramyxoviridae.
WO2019092027A1 (en)	2017-11-09	2019-05-16	Boehringer Ingelheim Vetmedica Gmbh	Sapelovirus immunogenic compositions and uses thereof
AR115256A1 (es)	2018-02-23	2020-12-16	Boehringer Ingelheim Vetmedica Gmbh	Sistemas de vectores virales recombinantes que expresan genes de paramixovirus felino exógenos y vacunas elaboradas a partir de estos
BR112020019268A2 (pt)	2018-03-19	2021-01-05	Boehringer Ingelheim Vetmedica Gmbh	Novo ehv com ul18 e/ou ul8 inativados
EP3768326A1 (en)	2018-03-19	2021-01-27	Boehringer Ingelheim Vetmedica GmbH	Ehv insertion site ul43
CN112088013A (zh)	2018-03-26	2020-12-15	勃林格殷格翰动物保健美国有限公司	制备免疫原性组合物的方法
TW202026010A (zh)	2018-09-20	2020-07-16	德商百靈佳殷格翰維美迪加股份有限公司	抗豬流行性下痢之鼻內載體疫苗
KR20210062015A (ko)	2018-09-20	2021-05-28	베링거잉겔하임베트메디카게엠베하	변형된 pedv 스파이크 단백질
IT201900007060A1 (it)	2019-05-21	2020-11-21	St Superiore Di Sanita	Cellule tumorali ingegnerizzate e loro usi
IT201900012540A1 (it)	2019-07-22	2021-01-22	Humanitas Mirasole Spa	Inibitori di CHI3L1 e loro usi
US11858962B2 (en)	2020-02-06	2024-01-02	Boehringer Ingelheim Vetmedica Gmbh	Polypeptides useful for detecting anti-rhabdovirus antibodies
CN116438202A (zh)	2020-10-05	2023-07-14	勃林格殷格翰动物保健美国有限公司	包含圆环病毒科衣壳蛋白的融合蛋白及其构成的嵌合病毒样颗粒
KR20230082653A (ko)	2020-10-05	2023-06-08	베링거잉겔하임베트메디카게엠베하	로타바이러스에 대한 백신 접종에 유용한 융합 단백질
WO2023194913A1 (en)	2022-04-05	2023-10-12	Boehringer Ingelheim Vetmedica Gmbh	Immunogenic composition useful for vaccination against rotavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL86354A0 (en) *	1987-05-22	1988-11-15	Orion Yhtymae Oy	Episomal vector for the expression of selected dna fragments coding for optional polypeptides in mammalian cells and methods for the production thereof
EP0465529B1 (en) *	1989-03-21	1998-04-29	Vical, Inc.	Expression of exogenous polynucleotide sequences in a vertebrate
US5643578A (en) *	1992-03-23	1997-07-01	University Of Massachusetts Medical Center	Immunization by inoculation of DNA transcription unit

1994
- 1994-03-09 IL IL10891594A patent/IL108915A0/xx unknown
- 1994-03-09 EP EP94200605A patent/EP0620277A1/en not_active Withdrawn
- 1994-03-14 NZ NZ263680A patent/NZ263680A/en unknown
- 1994-03-14 SI SI9420014A patent/SI9420014A/sl not_active IP Right Cessation
- 1994-03-14 CZ CZ19952373A patent/CZ290315B6/cs not_active IP Right Cessation
- 1994-03-14 SK SK1142-95A patent/SK114295A3/sk unknown
- 1994-03-14 HU HU9502702A patent/HUT73397A/hu unknown
- 1994-03-14 UA UA95094152A patent/UA42715C2/uk unknown
- 1994-03-14 WO PCT/US1994/002751 patent/WO1994021797A1/en active IP Right Grant
- 1994-03-14 PL PL94310677A patent/PL178626B1/pl unknown
- 1994-03-14 BR BR9406007A patent/BR9406007A/pt not_active Application Discontinuation
- 1994-03-14 CN CN94191485A patent/CN1119458A/zh active Pending
- 1994-03-14 RO RO95-01622A patent/RO117710B1/ro unknown
- 1994-03-16 DZ DZ940021A patent/DZ1759A1/fr active
- 1994-03-16 CA CA002119175A patent/CA2119175A1/en not_active Abandoned
- 1994-03-17 HR HR08/089,985A patent/HRP940175A2/xx not_active Application Discontinuation
- 1994-03-17 YU YU12894A patent/YU12894A/sh unknown
- 1994-03-17 AU AU57889/94A patent/AU676258B2/en not_active Ceased
- 1994-03-18 JP JP6049102A patent/JP2812352B2/ja not_active Expired - Fee Related
1995
- 1995-09-14 FI FI954329A patent/FI954329A0/fi unknown
- 1995-09-15 NO NO953649A patent/NO953649L/no not_active Application Discontinuation
- 1995-09-18 BG BG100006A patent/BG63126B1/bg unknown
1997
- 1997-10-22 JP JP29013797A patent/JP3608642B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU676258B2 (en)	1997-03-06
PL310677A1 (en)	1995-12-27
NZ263680A (en)	1997-05-26
JP3608642B2 (ja)	2005-01-12
HRP940175A2 (en)	1997-04-30
AU5788994A (en)	1994-09-22
SI9420014A (en)	1996-08-31
FI954329A (fi)	1995-09-14
EP0620277A1 (en)	1994-10-19
BR9406007A (pt)	1996-01-02
FI954329A0 (fi)	1995-09-14
JPH10113194A (ja)	1998-05-06
SK114295A3 (en)	1996-02-07
JPH0795888A (ja)	1995-04-11
JP2812352B2 (ja)	1998-10-22
NO953649D0 (no)	1995-09-15
UA42715C2 (uk)	2001-11-15
HUT73397A (en)	1996-07-29
HU9502702D0 (en)	1995-11-28
IL108915A0 (en)	1994-06-24
YU12894A (sh)	1997-12-05
DZ1759A1 (fr)	2002-02-17
WO1994021797A1 (en)	1994-09-29
BG100006A (bg)	1996-12-31
CZ237395A3 (en)	1996-02-14
CZ290315B6 (cs)	2002-07-17
NO953649L (no)	1995-11-17
RO117710B1 (ro)	2002-06-28
CA2119175A1 (en)	1994-09-19
CN1119458A (zh)	1996-03-27
PL178626B1 (pl)	2000-05-31

Publication	Publication Date	Title
AU676258B2 (en)	1997-03-06	Nucleic acid pharmaceuticals
AU734690B2 (en)	2001-06-21	Coordinate in vivo gene expression
CA2482946C (en)	2013-09-17	Multi plasmid system for the production of influenza virus
US6534312B1 (en)	2003-03-18	Vaccines comprising synthetic genes
CN114014937A (zh)	2022-02-08	稳定化的流感血凝素茎区三聚体及其用途
KR102557390B1 (ko)	2023-07-19	비-구조 단백질의 단편으로 구성된 뎅기 바이러스 키메라 폴리에피토프 및 이의 뎅기 바이러스 감염에 대한 면역원성 조성물에서의 용도
US20040087521A1 (en)	2004-05-06	Nucleic acid pharmaceuticals-influenza matrix
HUE025727T2 (en)	2016-04-28	Multi-plasmid system for producing influenza virus
CN115867561A (zh)	2023-03-28	SARS-CoV蛋白、核酸构建体、病毒样蛋白(VLP)的表达及其相关方法
CN116113427A (zh)	2023-05-12	天然外膜囊泡中的sars-cov-2受体结合结构域
CA2842055C (en)	2019-04-02	Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
US10894080B2 (en)	2021-01-19	Transgenic VERO-CD4/CCR5 cell line
AU3723099A (en)	1999-11-23	Attenuated influenza viruses
RU2193065C2 (ru)	2002-11-20	Конструкция днк (варианты), днк-вектор, иммуногенная композиция против вируса гриппа, способ индукции иммунного ответа, вакцина и способ вакцинации
MXPA01010481A (es)	2002-03-27	Acidos nucleicos y polipeptidos de lisavirus quimerico.
US9925258B2 (en)	2018-03-27	Replication-competent VSV-HIV Env vaccines
WO2023057766A1 (en)	2023-04-13	Influenza vaccines
Song et al.	2012	Recombinant influenza viruses as delivery vectors for hepatis B virus epitopes